Clinical trial
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations With H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of Age
NCT05874713 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations With H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of Age
- Lead sponsor
- Seqirus
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 7, 2023
- Completion date
- September 25, 2024
- Enrollment
- 480 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
infection viral, infections, influenza, human, respiratory tract infections, virus diseases